I don't know who you are. I don't agree with you or how you think., and more importantly, I do not believe your thesis that Tethadur is so far down the road that it has no value. If you can show me a company, in the realm of public or private companies that can show or state that they can deliver proteins, antibodies, or fragments thereof, I'm fricken' listening. STATE IT NOW! OR, go away, and do not respond to my posts or statements. What your watching right now in stock movement, is the difference in the two companies. The market is finally starting to realize that PSDV "IS" the company with the intellectual property , and it might just have the upper hand in the marketplace because of it .Get a fricken' grip and buy more ALIM. I respect this board and have for more years than you've been trading........ Anyone, other than you, can chime in.
You're pretty much clueless bro in that you don't recognize that the value that's been created over your recent purchase price is ENTIRELY related to Iluvien. Phase 3 trials for an indication that's likely to result in minor sales is a NON-EVENT. The other development is too far off. Your assertion that a 25 gauge needle somehow subverts Alimera rights is downright idiotic.
btw, Alimera has also tripled from recent lows like PSDV entirely related to guess what....ILUVIEN.
Recent events that have driven the value for ALIM and PSDV.
Alimera raises 40 million from insiders in November, Iluvien launches in Germany, Iluvien launches in the UK, NICE commission approves UK reimbursement, Iluvien re-files with the FDA, FDA accepts re-filing and sets PDUFA date to in October. RINGING ANY BELLS EINSTEIN??? I would look to give back a great deal of your gains if the FDA rejects Iluvien again. You might recover in several years if PSDV development works out.
You have to at some point expect some details from management. You cant keep imagining things will fall into place. It looks like you don't think Ozurdex will compete with Iluvien in DME, i dont. I don't live in la la land. That being said, i believe Iuvien will generate decent revenues ~ 100 mill peak.
Mickmack I like the passion for the company. You have been in this company much longer than I. I have been researching for a few months now and put an investment in based on the upcoming approval of Iluvien. The fact that psdv has the technology is a bonus for me. Are you viewing tethadur as the main reason a buyout would occur? It would be very nice to see some writeups/studies on the uses outside of ophthalmology. Get some PR and some money inflow. Cool technology definitely has value but big Investors like to have some idea of how and when these products will make money.
completely agree with patchen. While i continue to believe in Iluvien story and think $PSDV is undervalued, i am investing my real $$ and would question why it is taking over a week to close the proposed financing. It was supposed to be closed by 24th of July and its Aug 1st already. Ashton is a very smart guy and i believe in his work in Tethadur, but it feels like Tethadur today is the same place where it was 2 years ago. Where is the progress report? I think the tech evaluations are +ve, but again details have been scant.